{
  "paper_id": "PMC5778176",
  "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5778176/",
  "figures": {
    "figure_1": {
      "figure_number": "Figure 1",
      "title": "Fig. 1.",
      "caption": "Daily titrated basal insulin dose (LS means) for insulin-naive patients starting treatment with insulin glargine at a strength of 100 units per milliliter (Gla-100) or insulin glargine at a strength of 300 units per milliliter (Gla-300)",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/60d3/5778176/bfae790d6d04/12325_2017_651_Fig1_HTML.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/60d3/5778176/bfae790d6d04/12325_2017_651_Fig1_HTML.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/60d3/5778176/bfae790d6d04/12325_2017_651_Fig1_HTML.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/60d3/5778176/bfae790d6d04/12325_2017_651_Fig1_HTML.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "Fig1",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/60d3/5778176/bfae790d6d04/12325_2017_651_Fig1_HTML.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC5778176/images/figure_1.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/60d3/5778176/bfae790d6d04/12325_2017_651_Fig1_HTML.jpg"
    },
    "figure_2": {
      "figure_number": "Figure 2",
      "title": "Fig. 2.",
      "caption": "Preswitch and postswitch daily basal insulin dose for patients switching to treatment with insulin glargine at a strength of 100 units per milliliter (Gla-100) or insulin glargine at a strength of 300 units per milliliter (Gla-300)",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/60d3/5778176/a6a4a923726c/12325_2017_651_Fig2_HTML.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/60d3/5778176/a6a4a923726c/12325_2017_651_Fig2_HTML.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/60d3/5778176/a6a4a923726c/12325_2017_651_Fig2_HTML.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/60d3/5778176/a6a4a923726c/12325_2017_651_Fig2_HTML.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "Fig2",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/60d3/5778176/a6a4a923726c/12325_2017_651_Fig2_HTML.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC5778176/images/figure_2.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/60d3/5778176/a6a4a923726c/12325_2017_651_Fig2_HTML.jpg"
    }
  },
  "claims": [
    {
      "sentence": "No difference in the final titrated dose was observed in patients who started treatment with Gla-300 versus patients who started treatment with Gla-100 (LS mean 0.43 units per kilogram vs 0.44 units per kilogram; P = 0.77) (Fig. 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nDaily titrated basal insulin dose (LS means) for insulin-naive patients starting treatment with insulin glargine at a strength of 100 units per milliliter (Gla-100) or insulin glargine at a strength of 300 units per milliliter (Gla-300)After other covariates had been controlled for, the daily dose of basal insulin was significantly lower after switching to treatment with Gla-300 (Fig. 2), with the adjusted difference between the preswitch and postswitch values being −0.15 units per kilogram (95% CI −0.28 to −0.02 units per kilogram; P = 0.02).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nPreswitch and postswitch daily basal insulin dose for patients switching to treatment with insulin glargine at a strength of 100 units per milliliter (Gla-100) or insulin glargine at a strength of 300 units per milliliter (Gla-300)Preinitiation and Postinitiation Hemoglobin A1c Level and Hypoglycemia\nCompared with before treatment initiation, the mean hemoglobin A1c level was significantly lower after initiation of Gla-300 or Gla-100 treatment (LS mean change 1.21 percentage points and 1.12 percentage points , respectively; both P < 0.001); the difference was not statistically significant between Gla-300 and Gla-100 (P = 0.62) (Fig. 3a).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel a",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel a",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel a",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The annualized mean number of hypoglycemic events per patient-year was significantly lower following initiation of Gla-300 treatment versus Gla-100 treatment at similar daily doses (Fig. 3b) and the relative risk of hypoglycemic events after initiation of Gla-300 treatment versus Gla-100 treatment was 0.31 (95% CI 0.12–0.81; P = 0.018).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "LS least squaresRegardless of prior basal insulin dosing frequency (P = 0.976), the mean hemoglobin A1c level was significantly lower after switching to treatment with Gla-300 from treatment with another basal insulin (Fig. 4a ).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel a",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Regardless of prior basal insulin dosing frequency (P = 0.845), the annualized mean number of hypoglycemic events per patient-year was significantly lower after switching to treatment with Gla-300 from treatment with another basal insulin (Fig. 4b).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel b",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel b",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel b",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "No difference in the final titrated dose was observed in patients who started treatment with Gla-300 versus patients who started treatment with Gla-100 (LS mean 0.43 units per kilogram vs 0.44 units per kilogram; P = 0.77) (Fig. 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nDaily titrated basal insulin dose (LS means) for insulin-naive patients starting treatment with insulin glargine at a strength of 100 units per milliliter (Gla-100) or insulin glargine at a strength of 300 units per milliliter (Gla-300)After other covariates had been controlled for, the daily dose of basal insulin was significantly lower after switching to treatment with Gla-300 (Fig. 2), with the adjusted difference between the preswitch and postswitch values being −0.15 units per kilogram (95% CI −0.28 to −0.02 units per kilogram; P = 0.02).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nPreswitch and postswitch daily basal insulin dose for patients switching to treatment with insulin glargine at a strength of 100 units per milliliter (Gla-100) or insulin glargine at a strength of 300 units per milliliter (Gla-300)Preinitiation and Postinitiation Hemoglobin A1c Level and Hypoglycemia\nCompared with before treatment initiation, the mean hemoglobin A1c level was significantly lower after initiation of Gla-300 or Gla-100 treatment (LS mean change 1.21 percentage points and 1.12 percentage points , respectively; both P < 0.001); the difference was not statistically significant between Gla-300 and Gla-100 (P = 0.62) (Fig. 3a).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel a",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel a",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel a",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The annualized mean number of hypoglycemic events per patient-year was significantly lower following initiation of Gla-300 treatment versus Gla-100 treatment at similar daily doses (Fig. 3b) and the relative risk of hypoglycemic events after initiation of Gla-300 treatment versus Gla-100 treatment was 0.31 (95% CI 0.12–0.81; P = 0.018).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "LS least squaresRegardless of prior basal insulin dosing frequency (P = 0.976), the mean hemoglobin A1c level was significantly lower after switching to treatment with Gla-300 from treatment with another basal insulin (Fig. 4a ).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel a",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Regardless of prior basal insulin dosing frequency (P = 0.845), the annualized mean number of hypoglycemic events per patient-year was significantly lower after switching to treatment with Gla-300 from treatment with another basal insulin (Fig. 4b).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel b",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel b",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel b",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "No difference in the final titrated dose was observed in patients who started treatment with Gla-300 versus patients who started treatment with Gla-100 (LS mean 0.43 units per kilogram vs 0.44 units per kilogram; P = 0.77) (Fig. 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nDaily titrated basal insulin dose (LS means) for insulin-naive patients starting treatment with insulin glargine at a strength of 100 units per milliliter (Gla-100) or insulin glargine at a strength of 300 units per milliliter (Gla-300)After other covariates had been controlled for, the daily dose of basal insulin was significantly lower after switching to treatment with Gla-300 (Fig. 2), with the adjusted difference between the preswitch and postswitch values being −0.15 units per kilogram (95% CI −0.28 to −0.02 units per kilogram; P = 0.02).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nPreswitch and postswitch daily basal insulin dose for patients switching to treatment with insulin glargine at a strength of 100 units per milliliter (Gla-100) or insulin glargine at a strength of 300 units per milliliter (Gla-300)Preinitiation and Postinitiation Hemoglobin A1c Level and Hypoglycemia\nCompared with before treatment initiation, the mean hemoglobin A1c level was significantly lower after initiation of Gla-300 or Gla-100 treatment (LS mean change 1.21 percentage points and 1.12 percentage points , respectively; both P < 0.001); the difference was not statistically significant between Gla-300 and Gla-100 (P = 0.62) (Fig. 3a).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel a",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel a",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel a",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The annualized mean number of hypoglycemic events per patient-year was significantly lower following initiation of Gla-300 treatment versus Gla-100 treatment at similar daily doses (Fig. 3b) and the relative risk of hypoglycemic events after initiation of Gla-300 treatment versus Gla-100 treatment was 0.31 (95% CI 0.12–0.81; P = 0.018).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "LS least squaresRegardless of prior basal insulin dosing frequency (P = 0.976), the mean hemoglobin A1c level was significantly lower after switching to treatment with Gla-300 from treatment with another basal insulin (Fig. 4a ).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel a",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Regardless of prior basal insulin dosing frequency (P = 0.845), the annualized mean number of hypoglycemic events per patient-year was significantly lower after switching to treatment with Gla-300 from treatment with another basal insulin (Fig. 4b).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel b",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel b",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel b",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "No difference in the final titrated dose was observed in patients who started treatment with Gla-300 versus patients who started treatment with Gla-100 (LS mean 0.43 units per kilogram vs 0.44 units per kilogram; P = 0.77) (Fig. 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nDaily titrated basal insulin dose (LS means) for insulin-naive patients starting treatment with insulin glargine at a strength of 100 units per milliliter (Gla-100) or insulin glargine at a strength of 300 units per milliliter (Gla-300)After other covariates had been controlled for, the daily dose of basal insulin was significantly lower after switching to treatment with Gla-300 (Fig. 2), with the adjusted difference between the preswitch and postswitch values being −0.15 units per kilogram (95% CI −0.28 to −0.02 units per kilogram; P = 0.02).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nPreswitch and postswitch daily basal insulin dose for patients switching to treatment with insulin glargine at a strength of 100 units per milliliter (Gla-100) or insulin glargine at a strength of 300 units per milliliter (Gla-300)Preinitiation and Postinitiation Hemoglobin A1c Level and Hypoglycemia\nCompared with before treatment initiation, the mean hemoglobin A1c level was significantly lower after initiation of Gla-300 or Gla-100 treatment (LS mean change 1.21 percentage points and 1.12 percentage points , respectively; both P < 0.001); the difference was not statistically significant between Gla-300 and Gla-100 (P = 0.62) (Fig. 3a).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel a",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel a",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel a",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The annualized mean number of hypoglycemic events per patient-year was significantly lower following initiation of Gla-300 treatment versus Gla-100 treatment at similar daily doses (Fig. 3b) and the relative risk of hypoglycemic events after initiation of Gla-300 treatment versus Gla-100 treatment was 0.31 (95% CI 0.12–0.81; P = 0.018).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "LS least squaresRegardless of prior basal insulin dosing frequency (P = 0.976), the mean hemoglobin A1c level was significantly lower after switching to treatment with Gla-300 from treatment with another basal insulin (Fig. 4a ).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel a",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Regardless of prior basal insulin dosing frequency (P = 0.845), the annualized mean number of hypoglycemic events per patient-year was significantly lower after switching to treatment with Gla-300 from treatment with another basal insulin (Fig. 4b).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel b",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel b",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel b",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "No difference in the final titrated dose was observed in patients who started treatment with Gla-300 versus patients who started treatment with Gla-100 (LS mean 0.43 units per kilogram vs 0.44 units per kilogram; P = 0.77) (Fig. 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nDaily titrated basal insulin dose (LS means) for insulin-naive patients starting treatment with insulin glargine at a strength of 100 units per milliliter (Gla-100) or insulin glargine at a strength of 300 units per milliliter (Gla-300)After other covariates had been controlled for, the daily dose of basal insulin was significantly lower after switching to treatment with Gla-300 (Fig. 2), with the adjusted difference between the preswitch and postswitch values being −0.15 units per kilogram (95% CI −0.28 to −0.02 units per kilogram; P = 0.02).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nPreswitch and postswitch daily basal insulin dose for patients switching to treatment with insulin glargine at a strength of 100 units per milliliter (Gla-100) or insulin glargine at a strength of 300 units per milliliter (Gla-300)Preinitiation and Postinitiation Hemoglobin A1c Level and Hypoglycemia\nCompared with before treatment initiation, the mean hemoglobin A1c level was significantly lower after initiation of Gla-300 or Gla-100 treatment (LS mean change 1.21 percentage points and 1.12 percentage points , respectively; both P < 0.001); the difference was not statistically significant between Gla-300 and Gla-100 (P = 0.62) (Fig. 3a).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel a",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel a",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel a",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The annualized mean number of hypoglycemic events per patient-year was significantly lower following initiation of Gla-300 treatment versus Gla-100 treatment at similar daily doses (Fig. 3b) and the relative risk of hypoglycemic events after initiation of Gla-300 treatment versus Gla-100 treatment was 0.31 (95% CI 0.12–0.81; P = 0.018).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "LS least squaresRegardless of prior basal insulin dosing frequency (P = 0.976), the mean hemoglobin A1c level was significantly lower after switching to treatment with Gla-300 from treatment with another basal insulin (Fig. 4a ).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel a",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Regardless of prior basal insulin dosing frequency (P = 0.845), the annualized mean number of hypoglycemic events per patient-year was significantly lower after switching to treatment with Gla-300 from treatment with another basal insulin (Fig. 4b).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel b",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel b",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel b",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "No difference in the final titrated dose was observed in patients who started treatment with Gla-300 versus patients who started treatment with Gla-100 (LS mean 0.43 units per kilogram vs 0.44 units per kilogram; P = 0.77) (Fig. 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nDaily titrated basal insulin dose (LS means) for insulin-naive patients starting treatment with insulin glargine at a strength of 100 units per milliliter (Gla-100) or insulin glargine at a strength of 300 units per milliliter (Gla-300)After other covariates had been controlled for, the daily dose of basal insulin was significantly lower after switching to treatment with Gla-300 (Fig. 2), with the adjusted difference between the preswitch and postswitch values being −0.15 units per kilogram (95% CI −0.28 to −0.02 units per kilogram; P = 0.02).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nPreswitch and postswitch daily basal insulin dose for patients switching to treatment with insulin glargine at a strength of 100 units per milliliter (Gla-100) or insulin glargine at a strength of 300 units per milliliter (Gla-300)Preinitiation and Postinitiation Hemoglobin A1c Level and Hypoglycemia\nCompared with before treatment initiation, the mean hemoglobin A1c level was significantly lower after initiation of Gla-300 or Gla-100 treatment (LS mean change 1.21 percentage points and 1.12 percentage points , respectively; both P < 0.001); the difference was not statistically significant between Gla-300 and Gla-100 (P = 0.62) (Fig. 3a).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel a",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel a",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel a",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The annualized mean number of hypoglycemic events per patient-year was significantly lower following initiation of Gla-300 treatment versus Gla-100 treatment at similar daily doses (Fig. 3b) and the relative risk of hypoglycemic events after initiation of Gla-300 treatment versus Gla-100 treatment was 0.31 (95% CI 0.12–0.81; P = 0.018).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "LS least squaresRegardless of prior basal insulin dosing frequency (P = 0.976), the mean hemoglobin A1c level was significantly lower after switching to treatment with Gla-300 from treatment with another basal insulin (Fig. 4a ).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel a",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Regardless of prior basal insulin dosing frequency (P = 0.845), the annualized mean number of hypoglycemic events per patient-year was significantly lower after switching to treatment with Gla-300 from treatment with another basal insulin (Fig. 4b).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel b",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel b",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel b",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "No difference in the final titrated dose was observed in patients who started treatment with Gla-300 versus patients who started treatment with Gla-100 (LS mean 0.43 units per kilogram vs 0.44 units per kilogram; P = 0.77) (Fig. 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nDaily titrated basal insulin dose (LS means) for insulin-naive patients starting treatment with insulin glargine at a strength of 100 units per milliliter (Gla-100) or insulin glargine at a strength of 300 units per milliliter (Gla-300)After other covariates had been controlled for, the daily dose of basal insulin was significantly lower after switching to treatment with Gla-300 (Fig. 2), with the adjusted difference between the preswitch and postswitch values being −0.15 units per kilogram (95% CI −0.28 to −0.02 units per kilogram; P = 0.02).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nPreswitch and postswitch daily basal insulin dose for patients switching to treatment with insulin glargine at a strength of 100 units per milliliter (Gla-100) or insulin glargine at a strength of 300 units per milliliter (Gla-300)Preinitiation and Postinitiation Hemoglobin A1c Level and Hypoglycemia\nCompared with before treatment initiation, the mean hemoglobin A1c level was significantly lower after initiation of Gla-300 or Gla-100 treatment (LS mean change 1.21 percentage points and 1.12 percentage points , respectively; both P < 0.001); the difference was not statistically significant between Gla-300 and Gla-100 (P = 0.62) (Fig. 3a).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel a",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel a",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel a",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The annualized mean number of hypoglycemic events per patient-year was significantly lower following initiation of Gla-300 treatment versus Gla-100 treatment at similar daily doses (Fig. 3b) and the relative risk of hypoglycemic events after initiation of Gla-300 treatment versus Gla-100 treatment was 0.31 (95% CI 0.12–0.81; P = 0.018).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "LS least squaresRegardless of prior basal insulin dosing frequency (P = 0.976), the mean hemoglobin A1c level was significantly lower after switching to treatment with Gla-300 from treatment with another basal insulin (Fig. 4a ).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel a",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Regardless of prior basal insulin dosing frequency (P = 0.845), the annualized mean number of hypoglycemic events per patient-year was significantly lower after switching to treatment with Gla-300 from treatment with another basal insulin (Fig. 4b).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel b",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel b",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel b",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "No difference in the final titrated dose was observed in patients who started treatment with Gla-300 versus patients who started treatment with Gla-100 (LS mean 0.43 units per kilogram vs 0.44 units per kilogram; P = 0.77) (Fig. 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nDaily titrated basal insulin dose (LS means) for insulin-naive patients starting treatment with insulin glargine at a strength of 100 units per milliliter (Gla-100) or insulin glargine at a strength of 300 units per milliliter (Gla-300)After other covariates had been controlled for, the daily dose of basal insulin was significantly lower after switching to treatment with Gla-300 (Fig. 2), with the adjusted difference between the preswitch and postswitch values being −0.15 units per kilogram (95% CI −0.28 to −0.02 units per kilogram; P = 0.02).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nPreswitch and postswitch daily basal insulin dose for patients switching to treatment with insulin glargine at a strength of 100 units per milliliter (Gla-100) or insulin glargine at a strength of 300 units per milliliter (Gla-300)Preinitiation and Postinitiation Hemoglobin A1c Level and Hypoglycemia\nCompared with before treatment initiation, the mean hemoglobin A1c level was significantly lower after initiation of Gla-300 or Gla-100 treatment (LS mean change 1.21 percentage points and 1.12 percentage points , respectively; both P < 0.001); the difference was not statistically significant between Gla-300 and Gla-100 (P = 0.62) (Fig. 3a).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel a",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel a",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel a",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The annualized mean number of hypoglycemic events per patient-year was significantly lower following initiation of Gla-300 treatment versus Gla-100 treatment at similar daily doses (Fig. 3b) and the relative risk of hypoglycemic events after initiation of Gla-300 treatment versus Gla-100 treatment was 0.31 (95% CI 0.12–0.81; P = 0.018).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "LS least squaresRegardless of prior basal insulin dosing frequency (P = 0.976), the mean hemoglobin A1c level was significantly lower after switching to treatment with Gla-300 from treatment with another basal insulin (Fig. 4a ).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel a",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Regardless of prior basal insulin dosing frequency (P = 0.845), the annualized mean number of hypoglycemic events per patient-year was significantly lower after switching to treatment with Gla-300 from treatment with another basal insulin (Fig. 4b).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel b",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel b",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel b",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "No difference in the final titrated dose was observed in patients who started treatment with Gla-300 versus patients who started treatment with Gla-100 (LS mean 0.43 units per kilogram vs 0.44 units per kilogram; P = 0.77) (Fig. 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nDaily titrated basal insulin dose (LS means) for insulin-naive patients starting treatment with insulin glargine at a strength of 100 units per milliliter (Gla-100) or insulin glargine at a strength of 300 units per milliliter (Gla-300)After other covariates had been controlled for, the daily dose of basal insulin was significantly lower after switching to treatment with Gla-300 (Fig. 2), with the adjusted difference between the preswitch and postswitch values being −0.15 units per kilogram (95% CI −0.28 to −0.02 units per kilogram; P = 0.02).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nPreswitch and postswitch daily basal insulin dose for patients switching to treatment with insulin glargine at a strength of 100 units per milliliter (Gla-100) or insulin glargine at a strength of 300 units per milliliter (Gla-300)Preinitiation and Postinitiation Hemoglobin A1c Level and Hypoglycemia\nCompared with before treatment initiation, the mean hemoglobin A1c level was significantly lower after initiation of Gla-300 or Gla-100 treatment (LS mean change 1.21 percentage points and 1.12 percentage points , respectively; both P < 0.001); the difference was not statistically significant between Gla-300 and Gla-100 (P = 0.62) (Fig. 3a).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel a",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel a",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel a",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The annualized mean number of hypoglycemic events per patient-year was significantly lower following initiation of Gla-300 treatment versus Gla-100 treatment at similar daily doses (Fig. 3b) and the relative risk of hypoglycemic events after initiation of Gla-300 treatment versus Gla-100 treatment was 0.31 (95% CI 0.12–0.81; P = 0.018).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "LS least squaresRegardless of prior basal insulin dosing frequency (P = 0.976), the mean hemoglobin A1c level was significantly lower after switching to treatment with Gla-300 from treatment with another basal insulin (Fig. 4a ).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel a",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Regardless of prior basal insulin dosing frequency (P = 0.845), the annualized mean number of hypoglycemic events per patient-year was significantly lower after switching to treatment with Gla-300 from treatment with another basal insulin (Fig. 4b).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel b",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel b",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel b",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "No difference in the final titrated dose was observed in patients who started treatment with Gla-300 versus patients who started treatment with Gla-100 (LS mean 0.43 units per kilogram vs 0.44 units per kilogram; P = 0.77) (Fig. 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nDaily titrated basal insulin dose (LS means) for insulin-naive patients starting treatment with insulin glargine at a strength of 100 units per milliliter (Gla-100) or insulin glargine at a strength of 300 units per milliliter (Gla-300)After other covariates had been controlled for, the daily dose of basal insulin was significantly lower after switching to treatment with Gla-300 (Fig. 2), with the adjusted difference between the preswitch and postswitch values being −0.15 units per kilogram (95% CI −0.28 to −0.02 units per kilogram; P = 0.02).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "No difference in the final titrated dose was observed in patients who started treatment with Gla-300 versus patients who started treatment with Gla-100 (LS mean 0.43 units per kilogram vs 0.44 units per kilogram; P = 0.77) (Fig. 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "After other covariates had been controlled for, the daily dose of basal insulin was significantly lower after switching to treatment with Gla-300 (Fig. 2), with the adjusted difference between the preswitch and postswitch values being −0.15 units per kilogram (95% CI −0.28 to −0.02 units per kilogram; P = 0.02).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Preinitiation and Postinitiation Hemoglobin A1c Level and Hypoglycemia\nCompared with before treatment initiation, the mean hemoglobin A1c level was significantly lower after initiation of Gla-300 or Gla-100 treatment (LS mean change 1.21 percentage points and 1.12 percentage points , respectively; both P < 0.001); the difference was not statistically significant between Gla-300 and Gla-100 (P = 0.62) (Fig. 3a).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel a",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel a",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel a",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The annualized mean number of hypoglycemic events per patient-year was significantly lower following initiation of Gla-300 treatment versus Gla-100 treatment at similar daily doses (Fig. 3b) and the relative risk of hypoglycemic events after initiation of Gla-300 treatment versus Gla-100 treatment was 0.31 (95% CI 0.12–0.81; P = 0.018).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "LS least squaresRegardless of prior basal insulin dosing frequency (P = 0.976), the mean hemoglobin A1c level was significantly lower after switching to treatment with Gla-300 from treatment with another basal insulin (Fig. 4a ).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel a",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Regardless of prior basal insulin dosing frequency (P = 0.845), the annualized mean number of hypoglycemic events per patient-year was significantly lower after switching to treatment with Gla-300 from treatment with another basal insulin (Fig. 4b).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel b",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel b",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel b",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Compared with before treatment initiation, the mean hemoglobin A1c level was significantly lower after initiation of Gla-300 or Gla-100 treatment (LS mean change 1.21 percentage points and 1.12 percentage points , respectively; both P < 0.001); the difference was not statistically significant between Gla-300 and Gla-100 (P = 0.62) (Fig. 3a).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel a",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel a",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel a",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The annualized mean number of hypoglycemic events per patient-year was significantly lower following initiation of Gla-300 treatment versus Gla-100 treatment at similar daily doses (Fig. 3b) and the relative risk of hypoglycemic events after initiation of Gla-300 treatment versus Gla-100 treatment was 0.31 (95% CI 0.12–0.81; P = 0.018).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel b",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Regardless of prior basal insulin dosing frequency (P = 0.976), the mean hemoglobin A1c level was significantly lower after switching to treatment with Gla-300 from treatment with another basal insulin (Fig. 4a ).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel a",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Regardless of prior basal insulin dosing frequency (P = 0.845), the annualized mean number of hypoglycemic events per patient-year was significantly lower after switching to treatment with Gla-300 from treatment with another basal insulin (Fig. 4b).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel b",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel b",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel b",
          "figure_key": "figure_4"
        }
      ]
    }
  ],
  "extraction_stats": {
    "figures_count": 2,
    "claims_count": 66,
    "images_downloaded": 2,
    "tables_filtered": 173
  }
}